Abbott Laboratories

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $125.72, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.32%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BSX has a market cap of 152.6B. Regarding current trading prices, ABT is priced at $125.72, while BSX trades at $103.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BSX's P/E ratio is 75.31. In terms of profitability, ABT's ROE is +0.32%, compared to BSX's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SYK has a market cap of 151.1B. Regarding current trading prices, ABT is priced at $125.72, while SYK trades at $395.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SYK's P/E ratio is 53.42. In terms of profitability, ABT's ROE is +0.32%, compared to SYK's ROE of +0.11%. Regarding short-term risk, ABT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, MDT has a market cap of 117.4B. Regarding current trading prices, ABT is priced at $125.72, while MDT trades at $91.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas MDT's P/E ratio is 25.39. In terms of profitability, ABT's ROE is +0.32%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, EW has a market cap of 44.8B. Regarding current trading prices, ABT is priced at $125.72, while EW trades at $76.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas EW's P/E ratio is 31.53. In terms of profitability, ABT's ROE is +0.32%, compared to EW's ROE of +0.49%. Regarding short-term risk, ABT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, DXCM has a market cap of 33.4B. Regarding current trading prices, ABT is priced at $125.72, while DXCM trades at $85.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas DXCM's P/E ratio is 64.00. In terms of profitability, ABT's ROE is +0.32%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PHG has a market cap of 23.1B. Regarding current trading prices, ABT is priced at $125.72, while PHG trades at $25.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PHG's P/E ratio is 83.37. In terms of profitability, ABT's ROE is +0.32%, compared to PHG's ROE of +0.03%. Regarding short-term risk, ABT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, STE has a market cap of 22B. Regarding current trading prices, ABT is priced at $125.72, while STE trades at $223.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas STE's P/E ratio is 36.30. In terms of profitability, ABT's ROE is +0.32%, compared to STE's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PODD has a market cap of 20.1B. Regarding current trading prices, ABT is priced at $125.72, while PODD trades at $285.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PODD's P/E ratio is 52.02. In terms of profitability, ABT's ROE is +0.32%, compared to PODD's ROE of +0.35%. Regarding short-term risk, ABT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, ABT is priced at $125.72, while ZBH trades at $96.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ZBH's P/E ratio is 21.45. In terms of profitability, ABT's ROE is +0.32%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $125.72, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ALGN has a market cap of 14.1B. Regarding current trading prices, ABT is priced at $125.72, while ALGN trades at $194.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ALGN's P/E ratio is 35.29. In terms of profitability, ABT's ROE is +0.32%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, ABT is priced at $125.72, while SNN trades at $30.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SNN's P/E ratio is 32.91. In terms of profitability, ABT's ROE is +0.32%, compared to SNN's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $125.72, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.32%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PEN has a market cap of 9B. Regarding current trading prices, ABT is priced at $125.72, while PEN trades at $232.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PEN's P/E ratio is 214.84. In terms of profitability, ABT's ROE is +0.32%, compared to PEN's ROE of +0.04%. Regarding short-term risk, ABT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, GMED has a market cap of 7.2B. Regarding current trading prices, ABT is priced at $125.72, while GMED trades at $53.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas GMED's P/E ratio is 39.27. In terms of profitability, ABT's ROE is +0.32%, compared to GMED's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BIO-B has a market cap of 7B. Regarding current trading prices, ABT is priced at $125.72, while BIO-B trades at $257.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BIO-B's P/E ratio is -3.37. In terms of profitability, ABT's ROE is +0.32%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BIO has a market cap of 6.7B. Regarding current trading prices, ABT is priced at $125.72, while BIO trades at $245.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BIO's P/E ratio is -3.21. In terms of profitability, ABT's ROE is +0.32%, compared to BIO's ROE of -0.32%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BRKR has a market cap of 5.9B. Regarding current trading prices, ABT is priced at $125.72, while BRKR trades at $38.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BRKR's P/E ratio is 74.65. In terms of profitability, ABT's ROE is +0.32%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, GKOS has a market cap of 5.5B. Regarding current trading prices, ABT is priced at $125.72, while GKOS trades at $96.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas GKOS's P/E ratio is -42.48. In terms of profitability, ABT's ROE is +0.32%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $125.72, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.32%, compared to NARI's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, IRTC has a market cap of 4.3B. Regarding current trading prices, ABT is priced at $125.72, while IRTC trades at $133.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas IRTC's P/E ratio is -42.48. In terms of profitability, ABT's ROE is +0.32%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ITGR has a market cap of 4B. Regarding current trading prices, ABT is priced at $125.72, while ITGR trades at $114.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ITGR's P/E ratio is 53.19. In terms of profitability, ABT's ROE is +0.32%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, ABT is priced at $125.72, while INSP trades at $129.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas INSP's P/E ratio is 59.06. In terms of profitability, ABT's ROE is +0.32%, compared to INSP's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $125.72, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, TMDX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $125.72, while TMDX trades at $105.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas TMDX's P/E ratio is 74.37. In terms of profitability, ABT's ROE is +0.32%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PRCT has a market cap of 3.3B. Regarding current trading prices, ABT is priced at $125.72, while PRCT trades at $58.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PRCT's P/E ratio is -34.77. In terms of profitability, ABT's ROE is +0.32%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, ABT is priced at $125.72, while LIVN trades at $43.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas LIVN's P/E ratio is -10.70. In terms of profitability, ABT's ROE is +0.32%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $125.72, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $125.72, while UFPT trades at $231.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas UFPT's P/E ratio is 28.32. In terms of profitability, ABT's ROE is +0.32%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SSII has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $125.72, while SSII trades at $8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SSII's P/E ratio is -105.62. In terms of profitability, ABT's ROE is +0.32%, compared to SSII's ROE of -1.05%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $125.72, while ATEC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ATEC's P/E ratio is -9.42. In terms of profitability, ABT's ROE is +0.32%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $125.72, while CNMD trades at $48.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CNMD's P/E ratio is 12.54. In terms of profitability, ABT's ROE is +0.32%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $125.72, while AORT trades at $30.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AORT's P/E ratio is -59.57. In terms of profitability, ABT's ROE is +0.32%, compared to AORT's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $125.72, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $125.72, while AHCO trades at $9.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AHCO's P/E ratio is 16.34. In terms of profitability, ABT's ROE is +0.32%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $125.72, while ESTA trades at $43.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ESTA's P/E ratio is -13.93. In terms of profitability, ABT's ROE is +0.32%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $125.72, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.32%, compared to SILK's ROE of -0.29%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $125.72, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.32%, compared to FNA's ROE of -0.36%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, ABT is priced at $125.72, while TNDM trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas TNDM's P/E ratio is -5.49. In terms of profitability, ABT's ROE is +0.32%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, INMD has a market cap of 1B. Regarding current trading prices, ABT is priced at $125.72, while INMD trades at $14.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas INMD's P/E ratio is 6.46. In terms of profitability, ABT's ROE is +0.32%, compared to INMD's ROE of +0.25%. Regarding short-term risk, ABT is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, IART has a market cap of 936.4M. Regarding current trading prices, ABT is priced at $125.72, while IART trades at $12.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas IART's P/E ratio is -31.71. In terms of profitability, ABT's ROE is +0.32%, compared to IART's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $125.72, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SIBN has a market cap of 731.3M. Regarding current trading prices, ABT is priced at $125.72, while SIBN trades at $17.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SIBN's P/E ratio is -27.24. In terms of profitability, ABT's ROE is +0.32%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ABT is priced at $125.72, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CRY's P/E ratio is 425.71. In terms of profitability, ABT's ROE is +0.32%, compared to CRY's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, IRMD has a market cap of 715.9M. Regarding current trading prices, ABT is priced at $125.72, while IRMD trades at $56.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas IRMD's P/E ratio is 36.32. In terms of profitability, ABT's ROE is +0.32%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $125.72, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BFLY-WT has a market cap of 573.6M. Regarding current trading prices, ABT is priced at $125.72, while BFLY-WT trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.32%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AXGN has a market cap of 571.1M. Regarding current trading prices, ABT is priced at $125.72, while AXGN trades at $12.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AXGN's P/E ratio is -78.37. In terms of profitability, ABT's ROE is +0.32%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, KIDS has a market cap of 563.7M. Regarding current trading prices, ABT is priced at $125.72, while KIDS trades at $22.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas KIDS's P/E ratio is -12.93. In terms of profitability, ABT's ROE is +0.32%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CBLL has a market cap of 560.9M. Regarding current trading prices, ABT is priced at $125.72, while CBLL trades at $15.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CBLL's P/E ratio is -12.52. In terms of profitability, ABT's ROE is +0.32%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SMLR has a market cap of 554.2M. Regarding current trading prices, ABT is priced at $125.72, while SMLR trades at $40.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SMLR's P/E ratio is -16.82. In terms of profitability, ABT's ROE is +0.32%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AVNS has a market cap of 547.5M. Regarding current trading prices, ABT is priced at $125.72, while AVNS trades at $11.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AVNS's P/E ratio is -1.43. In terms of profitability, ABT's ROE is +0.32%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, ABT is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ZIMV has a market cap of 523M. Regarding current trading prices, ABT is priced at $125.72, while ZIMV trades at $18.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ZIMV's P/E ratio is -20.81. In terms of profitability, ABT's ROE is +0.32%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PACB has a market cap of 486.1M. Regarding current trading prices, ABT is priced at $125.72, while PACB trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PACB's P/E ratio is -0.59. In terms of profitability, ABT's ROE is +0.32%, compared to PACB's ROE of -1.70%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BFLY has a market cap of 469.8M. Regarding current trading prices, ABT is priced at $125.72, while BFLY trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BFLY's P/E ratio is -6.33. In terms of profitability, ABT's ROE is +0.32%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SRDX has a market cap of 456.2M. Regarding current trading prices, ABT is priced at $125.72, while SRDX trades at $31.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SRDX's P/E ratio is -22.79. In terms of profitability, ABT's ROE is +0.32%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SENS has a market cap of 444.9M. Regarding current trading prices, ABT is priced at $125.72, while SENS trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SENS's P/E ratio is -5.36. In terms of profitability, ABT's ROE is +0.32%, compared to SENS's ROE of -7.46%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, OFIX has a market cap of 434.9M. Regarding current trading prices, ABT is priced at $125.72, while OFIX trades at $11.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas OFIX's P/E ratio is -3.00. In terms of profitability, ABT's ROE is +0.32%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BVS has a market cap of 427.3M. Regarding current trading prices, ABT is priced at $125.72, while BVS trades at $6.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BVS's P/E ratio is -13.42. In terms of profitability, ABT's ROE is +0.32%, compared to BVS's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CTKB has a market cap of 411.6M. Regarding current trading prices, ABT is priced at $125.72, while CTKB trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CTKB's P/E ratio is -36.11. In terms of profitability, ABT's ROE is +0.32%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, TMCI has a market cap of 370.5M. Regarding current trading prices, ABT is priced at $125.72, while TMCI trades at $5.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas TMCI's P/E ratio is -6.93. In terms of profitability, ABT's ROE is +0.32%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, NNOX has a market cap of 348.8M. Regarding current trading prices, ABT is priced at $125.72, while NNOX trades at $5.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas NNOX's P/E ratio is -6.01. In terms of profitability, ABT's ROE is +0.32%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, ABT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, OM has a market cap of 335.8M. Regarding current trading prices, ABT is priced at $125.72, while OM trades at $18.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas OM's P/E ratio is -0.66. In terms of profitability, ABT's ROE is +0.32%, compared to OM's ROE of -1.45%. Regarding short-term risk, ABT is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PTHL has a market cap of 320.6M. Regarding current trading prices, ABT is priced at $125.72, while PTHL trades at $22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PTHL's P/E ratio is -450.00. In terms of profitability, ABT's ROE is +0.32%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, ABT is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CATX has a market cap of 318.8M. Regarding current trading prices, ABT is priced at $125.72, while CATX trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CATX's P/E ratio is -3.41. In terms of profitability, ABT's ROE is +0.32%, compared to CATX's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CLPT has a market cap of 317.4M. Regarding current trading prices, ABT is priced at $125.72, while CLPT trades at $11.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CLPT's P/E ratio is -14.78. In terms of profitability, ABT's ROE is +0.32%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, VREX has a market cap of 314.6M. Regarding current trading prices, ABT is priced at $125.72, while VREX trades at $7.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas VREX's P/E ratio is -7.36. In terms of profitability, ABT's ROE is +0.32%, compared to VREX's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, NPCE has a market cap of 306.7M. Regarding current trading prices, ABT is priced at $125.72, while NPCE trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas NPCE's P/E ratio is -11.40. In terms of profitability, ABT's ROE is +0.32%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SNWV has a market cap of 302.9M. Regarding current trading prices, ABT is priced at $125.72, while SNWV trades at $35.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SNWV's P/E ratio is -5.67. In terms of profitability, ABT's ROE is +0.32%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, ABT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, RXST has a market cap of 295M. Regarding current trading prices, ABT is priced at $125.72, while RXST trades at $7.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas RXST's P/E ratio is -11.00. In terms of profitability, ABT's ROE is +0.32%, compared to RXST's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CERS has a market cap of 274.3M. Regarding current trading prices, ABT is priced at $125.72, while CERS trades at $1.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CERS's P/E ratio is -14.35. In terms of profitability, ABT's ROE is +0.32%, compared to CERS's ROE of -0.35%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, QTRX has a market cap of 257.1M. Regarding current trading prices, ABT is priced at $125.72, while QTRX trades at $5.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas QTRX's P/E ratio is -4.44. In terms of profitability, ABT's ROE is +0.32%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, VMD has a market cap of 256.9M. Regarding current trading prices, ABT is priced at $125.72, while VMD trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas VMD's P/E ratio is 20.97. In terms of profitability, ABT's ROE is +0.32%, compared to VMD's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, MASS has a market cap of 253.2M. Regarding current trading prices, ABT is priced at $125.72, while MASS trades at $7.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas MASS's P/E ratio is -3.18. In terms of profitability, ABT's ROE is +0.32%, compared to MASS's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, MXCT has a market cap of 238.2M. Regarding current trading prices, ABT is priced at $125.72, while MXCT trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas MXCT's P/E ratio is -5.60. In terms of profitability, ABT's ROE is +0.32%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, TCMD has a market cap of 232.3M. Regarding current trading prices, ABT is priced at $125.72, while TCMD trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas TCMD's P/E ratio is 15.14. In terms of profitability, ABT's ROE is +0.32%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BWAY has a market cap of 228.7M. Regarding current trading prices, ABT is priced at $125.72, while BWAY trades at $12.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BWAY's P/E ratio is 55.00. In terms of profitability, ABT's ROE is +0.32%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, ABT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $125.72, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, CVRX has a market cap of 210.4M. Regarding current trading prices, ABT is priced at $125.72, while CVRX trades at $8.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas CVRX's P/E ratio is -3.77. In terms of profitability, ABT's ROE is +0.32%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, ABT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ABT is priced at $125.72, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas EYES's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.32%, compared to EYES's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, MGRM has a market cap of 207.2M. Regarding current trading prices, ABT is priced at $125.72, while MGRM trades at $5.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas MGRM's P/E ratio is -11.46. In terms of profitability, ABT's ROE is +0.32%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, ABT is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, BSGM has a market cap of 187.8M. Regarding current trading prices, ABT is priced at $125.72, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas BSGM's P/E ratio is -11.51. In terms of profitability, ABT's ROE is +0.32%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, SGHT has a market cap of 184.6M. Regarding current trading prices, ABT is priced at $125.72, while SGHT trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas SGHT's P/E ratio is -3.64. In terms of profitability, ABT's ROE is +0.32%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, PROF has a market cap of 174.3M. Regarding current trading prices, ABT is priced at $125.72, while PROF trades at $5.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas PROF's P/E ratio is -4.79. In terms of profitability, ABT's ROE is +0.32%, compared to PROF's ROE of -0.70%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, TLSI has a market cap of 170.9M. Regarding current trading prices, ABT is priced at $125.72, while TLSI trades at $4.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas TLSI's P/E ratio is -4.09. In terms of profitability, ABT's ROE is +0.32%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, INGN has a market cap of 170.5M. Regarding current trading prices, ABT is priced at $125.72, while INGN trades at $6.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas INGN's P/E ratio is -5.51. In terms of profitability, ABT's ROE is +0.32%, compared to INGN's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, RPID has a market cap of 161.3M. Regarding current trading prices, ABT is priced at $125.72, while RPID trades at $3.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas RPID's P/E ratio is -3.57. In terms of profitability, ABT's ROE is +0.32%, compared to RPID's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ANIK has a market cap of 157.3M. Regarding current trading prices, ABT is priced at $125.72, while ANIK trades at $10.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ANIK's P/E ratio is -14.63. In terms of profitability, ABT's ROE is +0.32%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ELMD has a market cap of 157.2M. Regarding current trading prices, ABT is priced at $125.72, while ELMD trades at $18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ELMD's P/E ratio is 23.73. In terms of profitability, ABT's ROE is +0.32%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, LNSR has a market cap of 155.6M. Regarding current trading prices, ABT is priced at $125.72, while LNSR trades at $13.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas LNSR's P/E ratio is -2.69. In terms of profitability, ABT's ROE is +0.32%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, ABT is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, RCEL has a market cap of 153.6M. Regarding current trading prices, ABT is priced at $125.72, while RCEL trades at $5.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas RCEL's P/E ratio is -2.65. In terms of profitability, ABT's ROE is +0.32%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, OWLT has a market cap of 135.8M. Regarding current trading prices, ABT is priced at $125.72, while OWLT trades at $8.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas OWLT's P/E ratio is -5.10. In terms of profitability, ABT's ROE is +0.32%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, ABT is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, LUNG has a market cap of 130.4M. Regarding current trading prices, ABT is priced at $125.72, while LUNG trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas LUNG's P/E ratio is -2.25. In terms of profitability, ABT's ROE is +0.32%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, ABT is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, LUCD has a market cap of 121.2M. Regarding current trading prices, ABT is priced at $125.72, while LUCD trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas LUCD's P/E ratio is -0.96. In terms of profitability, ABT's ROE is +0.32%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, AVR has a market cap of 118.6M. Regarding current trading prices, ABT is priced at $125.72, while AVR trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas AVR's P/E ratio is -0.92. In terms of profitability, ABT's ROE is +0.32%, compared to AVR's ROE of -2.92%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABT is priced at $125.72, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABT's ROE is +0.32%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, ABT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, FONR has a market cap of 99M. Regarding current trading prices, ABT is priced at $125.72, while FONR trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas FONR's P/E ratio is 12.77. In terms of profitability, ABT's ROE is +0.32%, compared to FONR's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 218.7B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $125.72, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 15.79, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.32%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.